191 related articles for article (PubMed ID: 37855069)
1. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
4. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
Viprakasit V; Hamdy MM; Hassab HMA; Sherief LM; Al-Bagshi M; Khattab M; Chuncharunee S; Dung PC; Küpesiz A; Shekhawat A; Sonawane Y; Perez LT; Slader C; Taher AT
Ann Hematol; 2023 Aug; 102(8):2039-2049. PubMed ID: 37227493
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
[TBL] [Abstract][Full Text] [Related]
7. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract][Full Text] [Related]
8. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
[TBL] [Abstract][Full Text] [Related]
9. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
10. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
[TBL] [Abstract][Full Text] [Related]
11. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload.
Chuansumrit A; Songdej D; Sirachainan N; Kadegasem P; Saisawat P; Sungkarat W; Kempka K; Tungbubpha N
Hemoglobin; 2024 Jan; 48(1):47-55. PubMed ID: 38369714
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
14. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
16. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I;
Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
Oyedeji CI; Crawford RD; Shah N
J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.
Panigrahi M; Swain TR; Jena RK; Panigrahi A; Debta N
Indian J Pharmacol; 2020; 52(3):172-178. PubMed ID: 32873999
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
